U.S. emergency department visits for cutaneous abscess have increased with the emergence of methicillin-resistant Staphylococcus aureus (MRSA). The role of antibiotics for patients with a drained abscess is unclear.
etween 1993 and 2005, annual emergency department visits for skin and softtissue infections in the United States increased from 1.2 million to 3.4 million, primarily because of an increased incidence of abscesses. 1, 2 During this period, community-associated methicillin-resistant Staphylococcus aureus (MRSA) emerged as the most common cause of purulent skin and soft-tissue infections in many parts of the world. 3 Trimethoprim-sulfamethoxazole, which has retained in vitro activity against communityassociated MRSA, is among the most commonly prescribed antibiotics to treat these infections. 4 The primary treatment of a cutaneous abscess is drainage. 5 Whether adjunctive antibiotics lead to improved outcomes in patients with uncomplicated abscesses or just more cost and side effects is unclear. Previous investigations, which had small numbers of participants, did not show a benefit of antibiotic treatment. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Larger studies are required to show relatively small differences in cure rates, because drainage alone may result in resolution in more than 80% of cases. 16 To determine the efficacy of adjunctive antibiotics, we compared outcomes among 1265 emergency department patients presenting with an uncomplicated cutaneous abscess and treated with drainage who were randomly assigned to receive trimethoprim-sulfamethoxazole or placebo.
Me thods

Design
We conducted a multicenter, double-blind, randomized trial to determine whether trimethoprim-sulfamethoxazole, administered for 7 days, would be superior to placebo in emergency department patients who had a skin abscess receiving drainage and who were treated on an outpatient basis. The full protocol and statistical analysis plan are available with the full text of this article at NEJM.org. The institutional review board at each site approved the trial. Trial sites and conduct are described in the Supplementary Appendix, available at NEJM.org.
Trial Population
From April 2009 to April 2013, we enrolled patients older than 12 years of age who had a cutaneous lesion that was suspected to be an abscess on the basis of physical examination and ultrasonography or examination alone and that was found to have purulent material on surgical exploration. We enrolled only participants who had a lesion that had been present for less than 1 week and that measured at least 2.0 cm in diameter (as measured from the borders of induration, if the lesion was fluctuant, or from the borders of the abscess cavity on ultrasonography, if the lesion was not fluctuant), and for whom their treating clinician intended outpatient treatment. Eligible patients had to agree to return for reevaluation and to provide written informed consent. Exclusion criteria are described in the Supplementary Appendix.
Interventions and Baseline Evaluation
Before initiation of the trial, trial personnel underwent standardized training on the general technique 17 and trial-specific procedures for incision and drainage (see the Supplementary Appendix). Using double-blind, Web-based randomization, we assigned participants in a 1:1 ratio to a 7-day course of trimethoprim-sulfamethoxazole (four single-strength pills, each containing 80 mg of trimethoprim and 400 mg of sulfamethoxazole, twice daily) or placebo (four pills containing microcrystalline cellulose, twice daily). The dose of trimethoprim-sulfamethoxazole was based on existing recommendations. 18 We dispensed the active drug or placebo in blister packs; the first dose was taken from the participant's blister pack and administered after drainage of the abscess and before discharge from the emergency department. A participant's studygroup assignment could be unblinded before the participant's completion of the trial only if the participant had a treatment failure or adverse event for which an acceptable alternative treatment could not be given and the participant's best care would be threatened if unblinding of the study-group assignment was delayed. An independent contract research organization (EMMES, Rockville, MD) that developed the randomization code performed centralized randomization, with assignments made independently at each site. Details of the randomization and blinding methods are available in the Supplementary Appendix. All medications and placebo were purchased.
We collected baseline clinical information, including the dimensions of the abscess cavity (assessed with the use of both ultrasonography and probe) and the dimensions of erythema and swelling or induration. We sent drainage specimens for standard aerobic bacterial culture and susceptibility testing at site hospitals. Investigators were not aware of the results of these tests.
Outcome Measures
We performed evaluations at follow-up visits on day 3 or 4 (during the treatment period), day 8 to 10 (end of the treatment period), day 14 to 21 (test-of-cure assessment), and day 49 to 63 (extended follow-up). We assessed adherence by inspecting blister packs for retained pills. If the participant lost the blister pack, we assessed adherence by means of the record on a memory aid (a booklet that was formatted according to date and time of dose and in which the participant recorded the doses taken) and participant interview.
Descriptions of trial populations, including the modified intention-to-treat 1 (mITT-1) population, the per-protocol population, and the Food and Drug Administration (FDA) guidance early end-point population, 19 and definitions of clinical cure and clinical failure are provided in Table 1 (the definition of and results for the modified intention-to-treat 2 [mITT-2] population are provided in the Supplementary Appendix). The primary outcome was clinical cure of the abscess lesion at the test-of-cure visit (i.e., 7 to 14 days after the end of the treatment period). Participants were classified as having had a clinical cure if they did not meet the criteria for clinical failure at or before the test-of-cure visit. Standardized physical examination criteria for clinical failure were developed by investigator consensus before the initiation of the trial and varied according to the time since the participant started receiving treatment or placebo, as described in detail in Table 1 . All participants who met failure criteria discontinued the treatment or placebo and started treatment with an antibiotic other than trimethoprim-sulfamethoxazole, in addition to undergoing any additional surgical drainage that was deemed necessary. For the mITT-1 analysis, participants who were lost to follow-up were considered to have had clinical failure, and
Population Description Outcome Definition
Modified intentionto-treat 1
Participants who took at least one dose of the active drug or placebo and had an in-person or telephone assessment through the test-of-cure visit, as well as those who withdrew from the trial, were lost to follow-up before final classification, or had missing or unassigned outcomes
Participants were considered to have had a clinical cure if they did not meet the criteria for clinical failure at or before the test-of-cure visit. The criteria for clinical failure were as follows: fever (attributable to the infection), an increase in the maximal dimension of erythema by >25% from baseline, or worsening of wound swelling and tenderness by the visit during the treatment period (day 3 or 4); fever, no decrease in the maximal dimension of erythema from baseline, or no decrease in swelling or tenderness by the visit at the end of the treatment period (day 8-10); and fever or more than minimal erythema, swelling, or tenderness by the test-of-cure visit (day 14-21). Participants who withdrew from the trial, were lost to followup before final classification, or had missing or unassigned outcomes were classified as having had clinical failure.
Per-protocol
Participants who either took ≥75% of the total doses of study drug or placebo during first 5 days and had an in-person test-of-cure visit or were determined to have had clinical failure before the testof-cure visit and received ≥75% of the doses provided during the first 48 hr of the treatment period
Participants were considered to have had a clinical cure if they did not meet the criteria for clinical failure (see examination criteria above) at or before the test-of-cure visit.
FDAGEEP 19
Participants who received at least one dose of study drug or placebo and completed the follow-up evaluation at 48-72 hr after the start of trial treatment A clinical response was defined by a decrease or no increase in the length, width, and area of erythema from baseline, no worsening in swelling or induration, and the absence of fever (i.e., temperature <37.7°C) on the basis of a trial clinician's assessment.
Safety
Participants who underwent randomization, received the active drug or placebo, and did not return 100% of the doses at the end of the treatment period Adverse events were coded according to the Medical Dictionary for Regulatory Activities, version 17.0. Investigators categorized adverse events as related or not related to the active drug or placebo.
* All participants who were deemed by a trial clinician to have had clinical failure discontinued the trial regimen and started antibiotic treatment other than trimethoprim-sulfamethoxazole. FDAGEEP denotes Food and Drug Administration guidance early end point. those who did not present for the test-of-cure visit but could be reached by telephone were classified as having had clinical failure if they reported new antibiotic treatment for their skin infection. Outcome-assessment methods and interrater agreement are described in the Supplementary Appendix. Secondary outcomes were specified before trial initiation and included composite cure (i.e., resolution of all symptoms and signs of infection, or improvement such that no additional antibiotic therapy or surgical drainage procedure was necessary), surgical drainage procedures, changes in erythema size, the presence of swelling or induration and tenderness, invasive infections (i.e., sepsis, bacteremia, endocarditis, osteomyelitis, septic arthritis, necrotizing fasciitis, or pneumonia), skin infections at the same site and at a different site, hospitalizations, similar infections in household contacts, days missed from normal activities, days missed from work or school, and days that analgesics were used.
Statistical Analysis
We designed our trial as a superiority trial. Our primary hypothesis was that the cure rate among participants with a drained cutaneous abscess who received trimethoprim-sulfamethoxazole would be greater than the cure rate among those who received placebo. We estimated that enrollment of 590 participants would provide a power of 90% to detect an absolute between-group difference of 7.5 percentage points, assuming a cure rate of 90% in the trimethoprim-sulfamethoxazole group in the per-protocol population, at a type I error rate of 5%. During a prespecified interim analysis, the sample-size estimate was revised to 1265 participants to reflect the observed cure rate. We designated the primary analysis as the between-group difference in clinical cure rates at the test-of-cure visit in the per-protocol population and also conducted analyses in the modified intention-to-treat and FDA guidance early end-point populations. We chose to conduct the primary outcome analysis in the per-protocol population to most precisely evaluate outcomes among participants who returned for physical evaluation and treatment effects among those with good adherence with a complete treatment course. A determination of superiority required the lower boundary of the 95% confidence interval for the between-group difference in clinical cure rates to be greater than zero. We analyzed secondary outcomes in the per-protocol population, for which relatively complete data were available, and report 95% confidence intervals of the between-group difference in outcome rates.
R esults
Characteristics of the Patients and of the Lesions
Of 1265 enrolled patients, 1247 (98.6%) were randomly assigned to trimethoprim-sulfamethoxazole or placebo and received at least one dose; 1057 participants (83.6%) qualified for the per-protocol population ( Fig. 1 ). Of 1247 who took at least one dose, 807 (64.7%) were determined to be 100% adherent (412 in the placebo Participants received a 7-day course of trial therapy; follow-up visits occurred on day 3 or 4 (during the treatment period), day 8 to 10 (end of the treatment period), day 14 to 21 (test-of-cure assessment), and day 49 to 63 (extended follow-up). The safety population included participants who received the study drug or placebo and did not return 100% of the doses at the end of the treatment period. The modified intentionto-treat 1 (mITT-1) population included participants who took at least one dose of active drug or placebo and had an in-person or telephone assessment through the test-of-cure visit, as well as those who withdrew from the trial, were lost to follow-up before final classification, or had missing or unassigned outcomes. The per-protocol population included participants who either took at least 75% of the doses provided during the first 5 days of the treatment period and had an in-person test-of-cure visit or were determined to have had clinical failure before the test-of-cure visit and took at least 75% of the doses provided during the first 48 hours of the treatment period. Participants who were excluded from the per-protocol population could have more than one reason for exclusion. The Food and Drug Administration guidance early end point (FDAGEEP) population included participants who took at least one dose of trial medication and completed the follow-up evaluation at 48 to 72 hours after the study drug or placebo was initiated. For information on the modified intention to treat 2 (mITT-2) population, see the Supplementary Appendix. TMP/SMX denotes trimethoprim-sulfamethoxazole. group and 395 in the trimethoprim-sulfamethoxazole group), and 214 (17.2%) took 76 to 99% of the doses (94 in the placebo group and 120 in the trimethoprim-sulfamethoxazole group). Baseline characteristics in the mITT-1 population are summarized in Table 2 . The median age was 35 years (range, 14 to 73), and 58.2% of the participants were male. A total of 95 participants (7.6%) had a history of MRSA infection. The median length, width, and depth of the abscesses, as measured by probe, were 2.5 cm, 2.0 cm, and 1.5 cm, respectively. The median length and width of erythema were 6.5 cm and 5.0 cm, respectively. MRSA was found in 45.3% of the participants; 97.4% of MRSA isolates were susceptible to trimethoprim-sulfamethoxazole. Of 410 MRSA isolates that were tested, 394 (96.1%) were CC8, Panton-Valentine leukocidin (PVL)-positive, and SCCmec type IV, traits that are strongly associated with pulsed-field gel electrophoresis (PFGE) type USA300.
Clinical Cure and Failure
Clinical cure rates are summarized in Table 3 and Figure S1 in the Supplementary Appendix. The abscess cure rate was 80.5% in the trimethoprim-sulfamethoxazole group and 73.6% in the placebo group in the mITT-1 population (difference, 6.9 percentage points; 95% confidence interval [CI], 2.1 to 11.7; P = 0.005). If we assumed that all participants in the mITT-1 population who were lost to follow-up (58 in the trimethoprim-sulfamethoxazole group and 39 in the placebo group) had a clinical cure rather than clinical failure, the cure rates would be 89.7% and 79.9%, respectively (difference, 9.8 percentage points; 95% CI, 5.7 to 13.9; P<0.001). In the per-protocol population, clinical cure occurred in 487 of 524 participants (92.9%) in the trimethoprim-sulfamethoxazole group versus 457 of 533 participants (85.7%) in the placebo group (difference, 7.2 percentage points; 95% CI, 3.2 to 11.2; P<0.001). The cure rate was significantly higher in the trimethoprim-sulfamethoxazole group than in the placebo group in the mITT-2 population but not in the FDA guidance early end-point population (i.e., participants in whom response was assessed at 48 to 72 hours). Except for two participants in the placebo group who received a subsequent diagnosis of a local invasive infection at the site of the original abscess lesion, all participants not lost to follow-up who were deemed to have had clinical failure ultimately had a resolution of their initial skin infection.
Secondary Outcomes
Secondary outcomes in the per-protocol population are summarized in Table 4 . Trimethoprimsulfamethoxazole was superior to placebo with respect to most secondary outcomes, resulting in lower rates of subsequent surgical drainage procedures ( By the test-of-cure visit (7 to 14 days after the end of the treatment period), invasive infections had developed in two participants (0.4%) in the trimethoprim-sulfamethoxazole group (unrelated to their original abscess) and in two participants (0.4%) in the placebo group (a necrotizing infection in the abdominal wall and prepatellar bursitis of the knee at the site of the original abscesses, both due to MRSA); by the extended follow-up visit (42 to 56 days after the end of the treatment period), an invasive infection had developed in one participant (0.2%) in the trimethoprim-sulfamethoxazole group (unrelated to the original abscess).
Adverse Events
Adverse events are described in the Supplementary Appendix. Overall rates of adverse events were similar in the trimethoprim-sulfamethoxazole group and the placebo group, and most events were considered to be mild. The most common adverse events involved the gastrointestinal system (42.7% and 36.1%, respectively); no cases of Clostridium difficile-associated diarrhea occurred. No treatment-associated serious or life-threatening adverse events occurred. Rates of treatment discontinuation due to adverse events were also similar in the two groups (1.9% and 0.6%, respectively). There were two deaths (one in each group); they were considered to be unrelated to the active drug or placebo.
Discussion
In this trial involving 1265 patients with a drained cutaneous abscess, we found that patients who received trimethoprim-sulfamethoxazole (at doses of 320 mg and 1600 mg, respectively, twice daily, for 7 days) had a higher cure rate than those who received placebo. We also found that many secondary outcomes were better in the trimethoprim-sulfamethoxazole group than in the placebo group, including fewer subsequent surgical drainage procedures, new skin infections, and infections among household members through 6 to 8 weeks after the end of the treatment period. Participants who received trimethoprim-sulfamethoxazole had only slightly more gastrointestinal side effects (mostly mild) than those who received placebo and had no serious or lifethreatening drug-related adverse reactions. Previous studies have not shown a benefit of adjunctive antibiotics. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] We are aware of two randomized, placebo-controlled trials since the emergence of community-associated MRSA that used an antibiotic active against these infections (i.e., trimethoprim-sulfamethoxazole), one involving 161 children and another involving 212 adults. 14, 15 Both studies failed to show a significant between-group difference in the short-term response rate with respect to the primary lesion.
Because cure rates with drainage alone among patients with simple abscesses may exceed 80%, studies with large sample sizes are necessary to test for small differences in response rates. Spellberg and colleagues 20 concluded that placebocontrolled studies suggesting an absolute advantage in cure rate with antibiotic treatment of 5 to 10 percentage points were underpowered to confirm this difference statistically. We powered our trial assuming an effect size of 7.5 percentage points and found that trimethoprim-sulfamethoxazole treatment resulted in a significantly higher abscess cure rate than did placebo.
We found that the cure rate with respect to the primary lesion was approximately 7 percent-age points higher with trimethoprim-sulfamethoxazole than with placebo. Thus, adjunctive oral treatment with trimethoprim-sulfamethoxazole -which is inexpensive, appears to be safe, and is associated with a higher cure rate of the primary lesion than that with placebo -offers the possibility of lower rates of costly subsequent medical visits, surgeries, and hospitalizations and of new infections among patients and their household contacts. On the other hand, drainage alone was associated with a similar rate of response at 48 to 72 hours and a high overall cure rate. Trimethoprim-sulfamethoxazole can cause uncommon but serious complications such C. difficile colitis, renal and electrolyte problems, drug interactions, and rare life-threatening reactions (e.g., Stevens-Johnson syndrome, at an estimated rate of 3 cases per 100,000 exposed persons 21 ). Increased antibiotic use may promote bacterial resistance. A similar National Institutes of Health-funded trial (ClinicalTrials.gov number, NCT00730028) may also shed light on the efficacy of adjunctive antibiotics.
Practice guidelines for abscess treatment state that drainage is sufficient for many patients and, primarily on the basis of expert opinion, recommend adjunctive antibiotics for patients who have certain clinical or demographic characteristics, including the systemic inflammatory response syndrome, diabetes, very young or very old age, an infected site with a diameter of more than 5 cm, and surrounding cellulitis. [22] [23] [24] Participants in this trial had typical skin abscesses, which were generally small (most only 2 to 3 cm). However, most participants had a total lesion size, including associated erythema, of more than 5 cm, and many met other guideline criteria for antibiotic treatment.
This trial has a number of limitations. First, although patients with common coexisting conditions, such as diabetes, were not excluded, physicians may have been biased against enrolling some patients who were perceived as being at higher risk. Second, although a combination of 160 mg of trimethoprim and 800 mg of sulfamethoxazole twice daily should achieve serum and blister fluid levels above MRSA minimal inhibitory concentrations, 25 we chose a dose of 320 mg of trimethoprim and 1600 mg of sulfamethoxazole twice daily to best test efficacy and for consistency with existing recommendations. 18 Third, we had some degree of nonadherence, which would bias against trimethoprimsulfamethoxazole, but the higher dose may have mitigated against inadequate treatment. Fourth, we provided training for adequate abscess drain-age; however, to the extent that some abscesses may not have been fully drained, potential cure rates could be higher, particularly in the placebo group. Fifth, the standardized methods we created to determine clinical failure that necessitated a change in the study regimen may not be valid, although we are unaware of any validated method, and ours had good interrater agreement and were associated with a high cure rate among those who could be assessed by this method (i.e., the per-protocol population). Finally, significant differences between treatment groups with respect to secondary outcomes may be due to chance, although these generally favored trimethoprim-sulfamethoxazole, and, in the case of subsequent infections at new sites, were consistent with results of secondary outcome analyses 2 Days that analgesics were used § 6.0±4.9 6.4±4.9 −0.4 * Plus-minus values are means ±SD. Participants received a 7-day course of trial therapy; follow-up visits occurred on day 3 or 4 (during the treatment period), day 8 to 10 (end of the treatment period), day 14 to 21 (test-of-cure assessment), and day 49 to 63 (extended follow-up). † Shown is the difference in percentage points or number of days. ‡ Composite clinical cure was defined as the resolution of all symptoms and signs of infection, or improvement to such an extent that no additional antibiotic therapy or surgical drainage procedure was necessary. § Data are based on participants' reports in the first 14 days. in previous studies. 14, 15 These outcomes should be further explored in future studies.
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